Search hospitals
>
Virginia
>
Fairfax
Virginia Cancer Specialists
Claim this profile
Fairfax, Virginia 22031
Global Leader in Lung Cancer
Global Leader in Solid Tumors
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Cancer
Conducts research for Pancreatic Cancer
440 reported clinical trials
19 medical researchers
Summary
Virginia Cancer Specialists is a medical facility located in Fairfax, Virginia. This center is recognized for care of Lung Cancer, Solid Tumors, Non-Small Cell Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Virginia Cancer Specialists is involved with conducting 440 clinical trials across 327 conditions. There are 19 research doctors associated with this hospital, such as Alexander Spira, MD, Alex Spira, MD, PhD, Mitul Gandhi, and M. Adham Salkeni, MD, FRCPC.
Area of expertise
Lung Cancer
Virginia Cancer Specialists has run 240 trials for Lung Cancer. Some of their research focus areas include:
Solid Tumors
Virginia Cancer Specialists has run 197 trials for Solid Tumors. Some of their research focus areas include:
Top PIs
Alexander Spira, MD
Virginia Cancer Specialists
4 years of reported clinical research
Alex Spira, MD, PhD
NEXT Oncology
6 years of reported clinical research
Mitul Gandhi
Virginia Cancer Specialists
3 years of reported clinical research
M. Adham Salkeni, MD, FRCPC
Virginia Cancer Specialists
2 years of reported clinical research
Clinical Trials running at Virginia Cancer Specialists
Lung Cancer
Solid Tumors
Breast Cancer
Non-Small Cell Lung Cancer
Cancer
Ovarian Cancer
Endometrial Cancer
Pancreatic Cancer
Melanoma
Squamous Cell Carcinoma
Zongertinib
for Lung Cancer
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any systemic therapy including chemotherapy for advanced or metastatic lung cancer. The purpose of this study is to find out whether a medicine called zongertinib (BI 1810631) can slow down the worsening of advanced non-small cell lung cancer better than the standard treatment available. Zongertinib may slow cancer cell growth by inhibiting HER2. This would prolong cancer re-occurrence and increase survival. Current standard treatment is pembrolizumab plus platinum-pemetrexed chemotherapy. Participants are put into 2 groups by chance. One group receives zongertinib at regular times throughout the study and the other group receives infusions of pembrolizumab, pemetrexed and cisplatin or carboplatin (pembrolizumab plus platinum-pemetrexed chemotherapy) into a vein. Participants may be in the study up to a maximum of 70 months. During this time, they visit the study site about every 3 weeks for study procedures. The doctors regularly check the size of the tumour with a CT or MRI scan, at the beginning of the study and every 6 weeks. After 18 months they check the tumour size every 12 weeks. Doctors regularly check whether the cancer has spread to other parts of the body. The doctors also regularly check participants' health and take note of any unwanted effects. The time it takes for the cancer to worsen is compared between the 2 groups to see whether the treatment works. The participants also fill in questionnaires about their symptoms and quality of life.
Recruiting
2 awards
Phase 3
9 criteria
Multiple Therapies
for Stage III Non-Small Cell Lung Cancer
This trial is testing different treatments to see how well they work and how safe they are. It focuses on patients with advanced lung cancer that cannot be removed by surgery and have specific biological markers. The goal is to find out if these treatments can stop the cancer from growing or spreading and improve patients' health.
Recruiting
2 awards
Phase 3
17 criteria
ONC-392 vs Chemotherapy
for Lung Cancer
This trial is testing gotistobart, a new drug that helps the immune system fight advanced lung cancer in patients who haven't responded to other treatments. It works by blocking a protein that allows cancer cells to hide from the immune system.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Virginia Cancer Specialists?
Virginia Cancer Specialists is a medical facility located in Fairfax, Virginia. This center is recognized for care of Lung Cancer, Solid Tumors, Non-Small Cell Lung Cancer, Cancer, Pancreatic Cancer and other specialties. Virginia Cancer Specialists is involved with conducting 440 clinical trials across 327 conditions. There are 19 research doctors associated with this hospital, such as Alexander Spira, MD, Alex Spira, MD, PhD, Mitul Gandhi, and M. Adham Salkeni, MD, FRCPC.
Where is Virginia Cancer Specialists located?
Virginia Cancer Specialists is located at 8613 Lee Highway, Fairfax, VA 22031.
Who should I call to ask about financial aid or insurance network?
Virginia Cancer Specialists offers comprehensive financial assistance for patients dealing with insurance and billing concerns. Patients can seek help from a Patient Benefit Specialist at their physician's location for insurance inquiries and verifications, or contact Patient Benefits Representatives (PBR) at Virginia Oncology Associates (VOA) locations for guidance on financial issues and assistance programs. For general insurance questions, the insurance coverage page on their website provides a list of accepted insurance companies, with additional coverage options available upon inquiry at the physician's office.
What insurance does Virginia Cancer Specialists accept?
**Virginia Cancer Specialists Insurance Information:** - Accepts a wide range of insurance plans including but not limited to Aetna US Healthcare, Anthem Blue Cross Blue Shield, Blue Cross Blue Shield North Carolina, CIGNA, Coventry Health Care, and United Healthcare. - Patients are advised to confirm their insurance plan's participation and be aware of their responsibilities like obtaining referrals and paying copayments, coinsurance, or deductibles. **Virginia Cancer Institute Insurance Information:** - Participates with many insurance plans in Central Virginia, with a commitment to staying informed on the changing medical insurance landscape. - Encourages patients to verify their insurance details and is prepared to assist with insurance queries.
What awards or recognition has Virginia Cancer Specialists received?
Virginia Cancer Specialists (VCS) has been re-accredited for the prestigious Accreditation Program for Excellence (APEx) distinction in 2022, showcasing its excellence in cancer care. It received the Clinical Trials Participation Award in 2016, highlighting its commitment to advancing cancer care through community-based clinical trials. The VCS Research Institute is recognized for its outstanding research program and efficient study start-up timelines.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.